Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Eva Klein
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Living Beings
Physiology
Anatomy
Disorders
Chemicals & Drugs
Procedures
Sign-in to see full Profile
Network (preview)
43
Klein, George
22
Nagy, Noémi
18
Yefenof, Eitan
12
Kis, Loránd
11
Masucci, Maria
8
Bejarano, Maria Teresa
7
Ehlin-Henriksson, Barbro
7
Maeda, Akihiko
7
Mellstedt, Håkan
7
Takahara, Miki
6
Ahrlund-Richter, Lars
6
Bandobashi, Kentaro
5
Liu, Anquan
5
Nishikawa, Jun
4
Teramoto, N
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Eva Klein (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Nagy Noemi; Matskova Liudmila; Hellman Ulf; Klein George; Klein Eva
The apoptosis modulating role of SAP (SLAM associated protein) contributes to the symptomatology of the X linked lymphoproliferative disease.
Cell cycle (Georgetown, Tex.) 2009;8(19):3086-90.
-
2009: Nagy Noémi; Matskova Liudmila; Kis Loránd L; Hellman Ulf; Klein George; Klein Eva
The proapoptotic function of SAP provides a clue to the clinical picture of X-linked lymphoproliferative disease.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(29):11966-71.
-
2008: Klein Eva; Liu Anquan; Claesson Hans-Erik
Activation of innate immunity by the leukotriene B 4 inhibits EBV induced B-cell transformation in cord-blood derived mononuclear cultures.
Immunology letters 2008;116(2):174-7.
-
2007: Markasz Laszlo; Stuber Gyorgy; Vanherberghen Bruno; Flaberg Emilie; Olah Eva; Carbone Ennio; Eksborg Staffan; Klein Eva; Skribek Henriette; Szekely Laszlo
Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells.
Molecular cancer therapeutics 2007;6(2):644-54.
-
2006: Klein Eva; Kis L L; Takahara M
Pathogenesis of Epstein-Barr virus (EBV)-carrying lymphomas.
Acta microbiologica et immunologica Hungarica 2006;53(4):441-57.
-
2006: Takahara Miki; Kis Loránd L; Nagy Noémi; Liu Anquan; Harabuchi Yasuaki; Klein George; Klein Eva
Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3.
International journal of cancer. Journal international du cancer 2006;119(12):2775-83.
-
2006: Kis Loránd L; Takahara Miki; Nagy Noémi; Klein George; Klein Eva
Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1.
Immunology letters 2006;104(1-2):83-8.
-
2006: Kis Lorand L; Takahara Miki; Nagy Noemi; Klein George; Klein Eva
IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines.
Blood 2006;107(7):2928-35.
-
2005: Anastasiadou E; Boccellato F; Cirone M; Kis L L; Klein E; Frati L; Faggioni A; Trivedi P
Epigenetic mechanisms do not control viral latency III in primary effusion lymphoma cells infected with a recombinant Epstein-Barr virus.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(10):1854-6.
-
2005: Klein George; Klein Eva
Surveillance against tumors--is it mainly immunological?
Immunology letters 2005;100(1):29-33.
-
2005: Bandobashi Kentaro; Liu Anquan; Nagy Noémi; Kis Loránd L; Nishikawa Jun; Björkholm Magnus; Klein George; Klein Eva
EBV infection induces expression of the transcription factors ATF-2/c-Jun in B lymphocytes but not in B-CLL cells.
Virus genes 2005;30(3):323-30.
-
2005: Kis Loránd L; Nishikawa Jun; Takahara Miki; Nagy Noémi; Matskova Liudmila; Takada Kenzo; Elmberger P Göran; Ohlsson Ann; Klein George; Klein Eva
In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2.
International journal of cancer. Journal international du cancer 2005;113(6):937-45.
-
2005: Liu Anquan; Arbiser Jack L; Holmgren Arne; Klein George; Klein Eva
PSK and Trx80 inhibit B-cell growth in EBV-infected cord blood mononuclear cells through T cells activated by the monocyte products IL-15 and IL-12.
Blood 2005;105(4):1606-13.
-
2004: Nagy N; Takahara M; Nishikawa J; Bourdon J C; Kis L L; Klein G; Klein E
Wild-type p53 activates SAP expression in lymphoid cells.
Oncogene 2004;23(53):8563-70.
-
2004: Nishikawa Jun; Kis Lorand L; Liu Anquan; Zhang Xiangning; Takahara Miki; Bandobashi Kentaro; Kiss Csaba; Nagy Noemi; Okita Kiwamu; Klein George; Klein Eva
Upregulation of LMP1 expression by histone deacetylase inhibitors in an EBV carrying NPC cell line.
Virus genes 2004;28(1):121-8.
-
2004: Klein E
Non-proliferative interactions of Epstein-Barr virus and human B lymphocytes.
Folia biologica 2004;50(3-4):131-5.
-
2003: Kis Loránd L; Nagy Noémi; Klein George; Klein Eva
Expression of SH2D1A in five classical Hodgkin's disease-derived cell lines.
International journal of cancer. Journal international du cancer 2003;104(5):658-61.
-
2003: Klein George; Klein Eva
Torbjörn Caspersson, 15 October 1910 - 7 December 1997.
Proceedings of the American Philosophical Society 2003;147(1):73-5.
-
2002: Nagy Noémi; Maeda Akihiko; Bandobashi Kentaro; Kis Loránd L; Nishikawa Jun; Trivedi Pankaj; Faggioni Alberto; Klein George; Klein Eva
SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation.
International journal of cancer. Journal international du cancer 2002;100(4):433-40.
-
2002: Nagy Noémi; Mattsson Karin; Maeda Akihiko; Liu Anquan; Székely László; Klein Eva
The X-linked lymphoproliferative disease gene product SAP is expressed in activated T and NK cells.
Immunology letters 2002;82(1-2):141-7.
-
2002: Liu Anquan; Klein George; Bandobashi Kentaro; Klein Eva; Nagy Noémi
SH2D1A expression reflects activation of T and NK cells in cord blood lymphocytes infected with EBV and treated with the immunomodulator PSK.
Immunology letters 2002;80(3):181-8.
-
2001: Maeda A; Bandobashi K; Nagy N; Teramoto N; Gogolák P; Pokrovskaja K; Székely L; Björkholm M; Klein G; Klein E
Epstein-barr virus can infect B-chronic lymphocytic leukemia cells but it does not orchestrate the cell cycle regulatory proteins.
Journal of human virology 2001;4(5):227-37.
-
2001: Bandobashi K; Maeda A; Teramoto N; Nagy N; Székely L; Taguchi H; Miyoshi I; Klein G; Klein E
Intranuclear localization of the transcription coadaptor CBP/p300 and the transcription factor RBP-Jk in relation to EBNA-2 and -5 in B lymphocytes.
Virology 2001;288(2):275-82.
-
2001: Maeda A; Kiss C; Chen F; Ehlin-Henriksson B; Nagy N; Szekely L; Takada K; Klein E; Klein G
EBNA promoter usage in EBV-negative Burkitt lymphoma cell lines converted with a neomycin-resistant EBV strain.
International journal of cancer. Journal international du cancer 2001;93(5):714-9.
-
2000: Nagy N; Cerboni C; Mattsson K; Maeda A; Gogolák P; Sümegi J; Lányi A; Székely L; Carbone E; Klein G; Klein E
SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines.
International journal of cancer. Journal international du cancer 2000;88(3):439-47.
-
2000: Teramoto N; Gogolák P; Nagy N; Maeda A; Kvarnung K; Björkholm T; Klein E
Epstein-Barr virus-infected B-chronic lymphocyte leukemia cells express the virally encoded nuclear proteins but they do not enter the cell cycle.
Journal of human virology 2000;3(3):125-36.
-
2000: Rajnavölgyi E; Nagy N; Thuresson B; Dosztányi Z; Simon A; Simon I; Karr R W; Ernberg I; Klein E; Falk K I
A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes.
International immunology 2000;12(3):281-93.
-
1999: Klein E; Teramoto N; Gogolák P; Nagy N; Björkholm M
LMP-1, the Epstein-Barr virus-encoded oncogene with a B cell activating mechanism similar to CD40.
Immunology letters 1999;68(1):147-54.
-
1998: Nagy N; Vánky F; Klein E
Tumor surveillance: expression of the transporter associated with antigen processing (TAP-1) in ex-vivo human tumor samples and its elevation by in vitro treatment with IFN-gamma and TNF-alpha.
Immunology letters 1998;64(2-3):153-60.
-
1998: Tomita Y; Avila-Cariño J; Yamamoto K; Mellstedt H; Klein E
Recognition of B-CLL cells experimentally infected with EBV by autologous T lymphocytes.
Immunology letters 1998;60(2-3):73-9.
-
1997: Vánky F; Nagy N; Hising C; Sjövall K; Larson B; Klein E
Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro.
Cancer immunology, immunotherapy : CII 1997;43(6):317-23.
-
1997: Avila-Cariño J; Lewin N; Tomita Y; Szeles A; Sandlund A; Mosolits S; Mellstedt H; Klein G; Klein E
B-CLL cells with unusual properties.
International journal of cancer. Journal international du cancer 1997;70(1):1-8.
-
1996: Avila-Cariño J; Andersson J; Mellstedt H; Klein E
B-CLL cells experimentally infected with EBV enter DNA synthesis, produce cytokines and stimulate T-lymphocytes.
Immunology letters 1996;54(1):45-52.
-
1996: Vánky F; Hising C; Sjöwall K; Larsson B; Klein E
Interferon-gamma and tumor necrosis factor-alpha treatment of ex vivo human carcinoma cells potentiates their interaction with allogeneic lymphocytes.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1996;16(3):201-7.
-
1995: Yefenof E; Gafanovitch I; Oron E; Bar M; Klein E
Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K.
Cancer immunology, immunotherapy : CII 1995;41(6):389-96.
-
1995: Vánky F; Hising C; Sjöwall K; Larsson B; Rodriguez L; Orre L; Klein E
Immunogenicity and immunosensitivity of ex vivo human carcinomas: interferon gamma and tumour necrosis factor alpha treatment of tumour cells potentiates their interaction with autologous blood lymphocytes.
Cancer immunology, immunotherapy : CII 1995;41(4):217-26.
-
1995: Chen F; Zou J Z; di Renzo L; Winberg G; Hu L F; Klein E; Klein G; Ernberg I
A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1.
Journal of virology 1995;69(6):3752-8.
-
1995: Lewin N; Avila-Cariño J; Minarovits J; Lennette E; Brautbar C; Mellstedt H; Klein G; Klein E
Detection of two Epstein-Barr-virus (EBV)-carrying leukemic cell clones in a patient with chronic lymphocytic leukemia (CLL).
International journal of cancer. Journal international du cancer 1995;61(2):159-64.
-
1995: Stuber G; Dillner J; Modrow S; Wolf H; Székely L; Klein G; Klein E
HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1.
International immunology 1995;7(4):653-63.
-
1995: Klein E; Avila-Cariño J
EBV infection of B-CLL cells in vitro potentiates their allostimulatory capacity if accompanied by acquisition of the activated phenotype.
Current topics in microbiology and immunology 1995;194():127-33.
-
1994: Avila-Cariño J; Lewin N; Yamamoto K; Tomita Y; Mellstedt H; Brodin B; Rosén A; Klein E
EBV infection of B-CLL cells in vitro potentiates their allostimulatory capacity if accompanied by acquisition of the activated phenotype.
International journal of cancer. Journal international du cancer 1994;58(5):678-85.
-
1994: Yefenof E; Magyarlaki T; Fenyo E M; Wahren B; Klein E
Alternative complement pathway activation by CD4+ T cells of HIV infected individuals: a possible role in AIDS pathogenesis.
International immunology 1994;6(9):1361-6.
-
1994: di Renzo L; Altiok A; Klein G; Klein E
Endogenous TGF-beta contributes to the induction of the EBV lytic cycle in two Burkitt lymphoma cell lines.
International journal of cancer. Journal international du cancer 1994;57(6):914-9.
-
1994: Altiok A; Jädersten M; Magyarlaki T; Klein E
Biphasic effect of transforming growth factor-beta on Epstein-Barr virus-induced activation of human tonsillar B cells.
Immunology letters 1994;40(2):111-5.
-
1994: Stuber G; Leder G H; Storkus W T; Lotze M T; Modrow S; Székely L; Wolf H; Klein E; Kärre K; Klein G
Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.
European journal of immunology 1994;24(3):765-8.
-
1994: Avila-Cariño J; Végh Z; Klein E
Generation of HLA-B55 restricted T lymphocyte mediated cytotoxicity against autologous LCL.
Molecular immunology 1994;31(1):59-63.
-
1994: Végh Z; Wang P; Vánky F; Hising C; Sjöwall K; Larsson B; Klein E
Cytotoxic susceptibility and defective MHC class I expression do not correlate with mutation of p53 in human carcinomas.
Cancer immunology, immunotherapy : CII 1994;38(1):71-3.
-
1993: Di Renzo L; Avila-Cariño J; Klein E
Induction of the lytic viral cycle in Epstein Barr virus carrying Burkitt lymphoma lines is accompanied by increased expression of major histocompatibility complex molecules.
Immunology letters 1993;38(3):207-14.
-
1993: Altiok A; Ehlin-Henriksson B; Klein E
Correlation between the growth-inhibitory effect of TGF-beta 1 and phenotypic characteristics in a panel of B-cell lines.
International journal of cancer. Journal international du cancer 1993;55(1):137-40.
-
1993: Carbone E; Stuber G; Andrée S; Franksson L; Klein E; Beretta A; Siccardi A G; Kärre K
Reduced expression of major histocompatibility complex class I free heavy chains and enhanced sensitivity to natural killer cells after incubation of human lymphoid lines with beta 2-microglobulin.
European journal of immunology 1993;23(8):1752-6.
-
1993: Kuraya M; Minarovits J; Okada H; Klein E
HRF20/CD59 complement regulatory protein expression is phenotype-dependent and inducible by the hypomethylating agent 5-azacytidine on Burkitt's lymphoma cell lines.
Immunology letters 1993;37(1):35-9.
-
1993: Végh Z; Wang P; Vánky F; Klein E
Increased expression of MHC class I molecules on human cells after short time IFN-gamma treatment.
Molecular immunology 1993;30(9):849-54.
-
1993: Végh Z; Wang P; Vánky F; Klein E
Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors.
Cancer research 1993;53(10 Suppl):2416-20.
-
1992: Stuber G; Avila-Cariño J; Klein E
Generation of cytotoxicity with various MHC class I restrictions against autologous LCL by stimulating the lymphocytes with autologous and/or allogeneic LCLs sharing HLA alleles with the responder.
Cellular immunology 1992;145(1):66-77.
-
1992: Wang P; Végh Z s; Vánky F; Klein E
HLA-B5-restricted auto-tumor-specific cytotoxic T cells generated in mixed lymphocyte-tumor-cell culture.
International journal of cancer. Journal international du cancer 1992;52(4):517-22.
-
1992: Wang P; Vánky F; Végh Z; Persson U; Hising C; Klein E
Assembly of MHC class I molecules in ex vivo carcinoma cells induced by IFN-gamma or by a binding peptide.
Cellular immunology 1992;142(2):296-302.
-
1992: Wang P; Vánky F; Klein E
MHC class-I-restricted auto-tumor-specific CD4+CD8- T-cell clones established from autologous mixed lymphocyte-tumor-cell culture (MLTC).
International journal of cancer. Journal international du cancer 1992;51(6):962-7.
-
1992: Kuraya M; Yefenof E; Klein G; Klein E
Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
European journal of immunology 1992;22(7):1871-6.
-
1992: Altiok A; Bejarano M T; Klein G; Klein E
Effect of TGF-beta 1 on the EBV-induced transformation of human lymphocyte cultures.
International journal of cancer. Journal international du cancer 1992;50(5):772-6.
-
1992: Vánky F; Wang P; Klein E
The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells.
Cancer immunology, immunotherapy : CII 1992;35(3):193-8.
-
1991: Stuber G; Vánky F; Wen T; Chan A; Klein E; Mak T W
Predominant rearrangements of the T cell receptor beta-chain gene in blood lymphocyte populations stimulated with autologous tumor cells suggest clonal T cell expansion in two of fourteen cases.
Immunology letters 1991;30(3):313-8.
-
1991: Torsteinsdottir S; Cuomo L; Klein E; Masucci M G
Stimulation with allogeneic Epstein-Barr virus-transformed lymphoblastoid cell lines generates HLA class I-specific CTLs with different target cell avidity.
Cellular immunology 1991;137(2):501-13.
-
1991: Di Renzo L; Yefenof E; Klein E
The function of human NK cells is enhanced by beta-glucan, a ligand of CR3 (CD11b/CD18).
European journal of immunology 1991;21(7):1755-8.
-
1991: Yefenof E; Asjö B; Klein E
Alternative complement pathway activation by HIV infected cells: C3 fixation does not lead to complement lysis but enhances NK sensitivity.
International immunology 1991;3(4):395-401.
-
1991: Lewin N; Minarovits J; Weber G; Ehlin-Henriksson B; Wen T; Mellstedt H; Klein G; Klein E
Clonality and methylation status of the Epstein-Barr virus (EBV) genomes in in vivo-infected EBV-carrying chronic lymphocytic leukemia (CLL) cell lines.
International journal of cancer. Journal international du cancer 1991;48(1):62-6.
-
1991: Vánky F; Klein E
Requirement of MHC class I antigen expression on human tumors for in vitro recognition by autologous blood lymphocytes.
Seminars in cancer biology 1991;2(1):55-62.
-
1991: Masucci M G; Klein E
Cell phenotype dependent expression of MHC class I antigens in Burkitt's lymphoma cell lines.
Seminars in cancer biology 1991;2(1):63-71.
-
1991: Wang P; Vánky F; Li S L; Végh Z; Persson U; Klein E
Expression of MHC-class-I antigens in human carcinomas and sarcomas analyzed by isoelectric focusing.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1991;6():106-16.
-
1991: Wang P; Vánky F; Klein E
Application of isoelectric focusing for studies of major histocompatibility complex class I antigen expression on human carcinomas and sarcomas.
Cancer immunology, immunotherapy : CII 1991;33(1):65-9.
-
1991: Yefenof E; Einat E; Klein E
Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K.
Cancer immunology, immunotherapy : CII 1991;34(2):133-7.
-
1991: Avila-Cariño J; Torsteinsdottir S; Ehlin-Henriksson B; Masucci M G; Klein E
Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes.
Cancer immunology, immunotherapy : CII 1991;34(2):128-32.
-
1991: Yefenof E; Algarra I; Ramos O F; Klein E
Activation and fixation of C3 by human B cell lines is enhanced by interferon-gamma and tumor necrosis factor alpha.
Complement and inflammation 1991;8(5-6):271-80.
-
1991: Altiok A; Bejarano M T; Ruscetti F; Altiok E; Klein G; Klein E
Effect of transforming growth factor-beta 1 and -beta 2 on the proliferation of Burkitt lymphoma and lymphoblastoid cell lines.
Growth factors (Chur, Switzerland) 1991;4(2):117-28.
-
1990: Klein E; Di Renzo L; Yefenof E
Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells.
Molecular immunology 1990;27(12):1343-7.
-
1990: Wang P; Vánky F; Li S L; Patarroyo M; Klein E
Functional characteristics of the intercellular adhesion molecule-1 (CD54) expressed on cytotoxic human blood lymphocytes.
Cellular immunology 1990;131(2):366-80.
-
1990: Lewin N; Aman P; Akerlund B; Gustavsson E; Carenfelt C; Lejdeborn L; Klein G; Klein E
Epstein-Barr virus-carrying B cells in the blood during acute infectious mononucleosis give rise to lymphoblastoid lines in vitro by release of transforming virus and by proliferation.
Immunology letters 1990;26(1):59-65.
-
1990: Kuraya M; Nilsson B; Nilsson-Ekdahl K; Klein E
C3d-mediated negative and positive signals on the proliferation of human B cells separated from blood.
Immunology letters 1990;26(1):51-8.
-
1990: Lewin N; Aman P; Mellstedt H; Carenfelt C; Klein G; Klein E
Epstein Barr virus (EBV) carrying cells in blood of Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL) patients with high antibody titers against EBV capsid antigens (VCA).
Anticancer research 1990;10(5A):1213-6.
-
1990: Bejarano M T; Masucci M G; Morgan A; Morein B; Klein G; Klein E
Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation.
Journal of virology 1990;64(3):1398-401.
-
1990: Yefenof E; Benizri R; Reiter Y; Klein E; Fishelson Z
Potentiation of NK cytotoxicity by antibody-C3b/iC3b heteroconjugates.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(4):1538-43.
-
1990: Aman P; Rowe M; Kai C; Finke J; Rymo L; Klein E; Klein G
Effect of the EBNA-2 gene on the surface antigen phenotype of transfected EBV-negative B-lymphoma lines.
International journal of cancer. Journal international du cancer 1990;45(1):77-82.
-
1990: Stuber G; Vánky F; Pócsik E; Benczúr M; Klein E
Expression of interleukin-2 receptor on blood lymphocytes stimulated with allogeneic lymphocytes or autologous tumor cells. The mixed lymphocyte culture of allo-sensitized individuals and the auto-tumor stimulation show similar kinetics of activation.
Cancer immunology, immunotherapy : CII 1990;31(2):76-80.
-
1990: Vánky F; Wang P; Patarroyo M; Klein E
Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro.
Cancer immunology, immunotherapy : CII 1990;31(1):19-27.
-
1990: Altiok A; Bejarano M T; Klein E
Effect of TGF-beta on the proliferation of B cell lines and on the immortalisation of B cells by EBV.
Current topics in microbiology and immunology 1990;166():375-80.
-
1989: Kurakata S; Ramos O F; Klein G; Klein E
Lysis of P3HR-1 cells induced to enter the viral cycle by antibody-dependent and independent immunological mechanisms.
Cellular immunology 1989;123(1):134-47.
-
1989: Ramos O F; Patarroyo M; Yefenof E; Klein E
Requirement of leukocytic cell adhesion molecules (CD11a-c/CD18) in the enhanced NK lysis of iC3b-opsonized targets.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(11):4100-4.
-
1989: Yefenof E; Ramos O F; Nilsson B; Klein E
Ligands of CR2 do not interfere with C3 fragment fixation or enhanced NK sensitivity of Raji cells treated with human serum.
Immunology letters 1989;21(4):303-6.
-
1989: Ohlén C; Bejarano M T; Grönberg A; Torsteinsdottir S; Franksson L; Ljunggren H G; Klein E; Klein G; Kärre K
Studies of sublines selected for loss of HLA expression from an EBV-transformed lymphoblastoid cell line. Changes in sensitivity to cytotoxic T cells activated by allostimulation and natural killer cells activated by IFN or IL-2.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(9):3336-41.
-
1989: Ramos O F; Nilsson B; Nilsson K; Eggertsen G; Yefenof E; Klein E
Elevated NK-mediated lysis of Raji and Daudi cells carrying fixed iC3b fragments.
Cellular immunology 1989;119(2):459-69.
-
1989: Torsteinsdóttir S; Andersson M L; Avila-Cariño J; Ehlin-Henriksson B; Masucci M G; Klein G; Klein E
Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line.
International journal of cancer. Journal international du cancer 1989;43(2):273-8.
-
1989: Ramos O F; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(1):217-23.
-
1989: Vánky F; Klein E
Auto-tumor lysis by blood lymphocytes in vitro. Strongly activated lymphocytes lack selectivity.
Cancer immunology, immunotherapy : CII 1989;29(2):125-32.
-
1989: Vánky F; Stuber G; Rotstein S; Klein E
Auto-tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC-antigen-negative tumor cells.
Cancer immunology, immunotherapy : CII 1989;28(1):17-21.
-
1988: Avila-Carino J; Torsteinsdottir S; Bejarano M T; Klein G; Klein E; Masucci M G
Combined treatment with interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha up-regulates the expression of HLA class I determinants in Burkitt lymphoma lines.
Cellular immunology 1988;117(2):303-11.
-
1988: Klein E; Ramos O; Sàrmay G; Yefenof E; Gergely J
Lysis of CR2-carrying cells by natural killer cells and by activated T-lymphocytes is enhanced by C3 fragments.
Molecular immunology 1988;25(11):1063-6.
-
1988: Kai C; Szigeti R; Aman P; Klein E
Activation of B lymphocytes with human serum-treated zymosan.
Cellular immunology 1988;116(2):467-74.
-
1988: Bejarano M T; Masucci M G; Klein G; Klein E
T-cell-mediated inhibition of EBV-induced B-cell transformation: recognition of virus particles.
International journal of cancer. Journal international du cancer 1988;42(3):359-64.
-
1988: Sulitzeanu D; Szigeti R; Hatzubai A; Dillner J; Hammarskjöld M L; Klein G; Klein E
Antibodies in human sera against the Epstein-Barr virus encoded latent membrane protein (LMP).
Immunology letters 1988;18(4):301-6.
-
1988: Torsteinsdottir S; Brautbar C; Klein G; Klein E; Masucci M G
Differential expression of HLA antigens on human B-cell lines of normal and malignant origin: a consequence of immune surveillance or a phenotypic vestige of the progenitor cells?
International journal of cancer. Journal international du cancer 1988;41(6):913-9.
-
1988: Kai C; Sármay G; Ramos O; Yefenof E; Klein E
Elevated NK sensitivity of Raji cells carrying acceptor-bound C3 fragments.
Cellular immunology 1988;113(2):227-34.
-
1988: Ramos O F; Kai C; Yefenof E; Klein E
The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments require the availability of the iC3b receptor (CR3) on the effectors.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(4):1239-43.
-
1988: Ahrlund-Richter L; Klein E
Resistance to growth of the Moloney lymphoma YAC in semi-syngeneic graft recipients.
International journal of cancer. Journal international du cancer 1988;41(1):123-6.
-
1988: Vánky F; Stuber G; Willems J; Sjöwall K; Larsson B; Böök K; Ivert T; Péterffy A; Klein E
Importance of MHC antigen expression on solid tumors in the in vitro interaction with autologous blood lymphocytes.
Cancer immunology, immunotherapy : CII 1988;27(3):213-22.
-
1987: Avila-Cariño J; Torsteinsdottir S; Ehlin-Henriksson B; Lenoir G; Klein G; Klein E; Masucci M G
Paired Epstein-Barr virus (EBV)-negative and EBV-converted Burkitt lymphoma lines: stimulatory capacity in allogeneic mixed lymphocyte cultures.
International journal of cancer. Journal international du cancer 1987;40(5):691-7.
-
1987: Vánky F; Roberts T; Klein E; Willems J
Auto-tumor immunity in patients with solid tumors: participation of CD3 complex and MHC class I antigens in the lytic interaction.
Immunology letters 1987;16(1):21-6.
-
1987: Ramos O F; Sármay G; Eggertsen G; Nilsson B; Klein E; Gergely J
Alternative pathway of complement activation by stimulated T lymphocytes. II. Elevation of cytotoxic potential against complement receptor-carrying cell lines.
European journal of immunology 1987;17(7):975-9.
-
1987: Sármay G; Ramos O F; Klein E; Kai C; Gergely J
Alternative pathway of complement activation by stimulated T lymphocytes. I. Binding of C3 fragments.
European journal of immunology 1987;17(7):969-74.
-
1987: Vánky F; Klein E; Willems J; Böök K; Ivert T; Péterffy A; Nilsonne U; Kreicbergs A
Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture--no correlation with the postsurgical clinical course.
Cancer immunology, immunotherapy : CII 1987;24(2):180-3.
-
1986: Klein E; Sármay G; Ramos O; Yefenof E; Gergely J
Contribution of activated C3 to lymphocyte-mediated cytolysis.
Molecular immunology 1986;23(11):1257-62.
-
1986: Torsteinsdottir S; Masucci M G; Ehlin-Henriksson B; Brautbar C; Ben Bassat H; Klein G; Klein E
Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(15):5620-4.
-
1986: Vánky F; Klein E; Willems J; Böök K; Ivert T; Péterffy A; Nilsonne U; Kreicbergs A; Aparisi T
Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery. Correlation with the postsurgical clinical course.
Cancer immunology, immunotherapy : CII 1986;21(1):69-76.
-
1985: Ramos O F; Sármay G; Klein E; Yefenof E; Gergely J
Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(16):5470-4.
-
1985: Torsteinsdottir S; Masucci M G; Bejarano M T; Berthold W; Klein E; Klein G
Selective inhibitory effect of Hu-IFN-gamma on the agarose clonability of tumor-derived lymphoid cell lines.
Cellular immunology 1985;90(1):65-73.
-
1984: Ahrlund-Richter L; Wikström A C; Ramqvist T; Klein E
The Lyt phenotype of the T cells in an antitumor adoptive transfer differs for "parent to F1" and "parent to parent" combinations.
Cellular immunology 1984;86(2):575-82.
-
1983: Ahrlund-Richter L; Merino F; Klein E
Role of H-2 antigens in the host response against transplanted methylcholanthrene-induced tumors. II. In vitro studies.
Immunogenetics 1983;18(2):159-63.
-
1983: Vánky F; Péterffy A; Böök K; Willems J; Klein E; Klein G
Correlation between lymphocyte-mediated auto-tumor reactivities and the clinical course. II. Evaluation of 69 patients with lung carcinoma.
Cancer immunology, immunotherapy : CII 1983;16(1):17-22.
-
1983: Vánky F; Willems J; Kreicbergs A; Aparisi T; Andréen M; Broström L A; Nilsonne U; Klein E; Klein G
Correlation between lymphocyte-mediated auto-tumor reactivities and clinical course. I. Evaluation of 46 patients with sarcoma.
Cancer immunology, immunotherapy : CII 1983;16(1):11-6.
-
1982: Ahrlund-Richter L; Klein E; Merino F
Role of H-2 antigens in the host response to methylcholanthrene-induced tumors.
Immunogenetics 1982;15(1):53-62.
-
1982: Vánky F; Klein E
Human T-cell cultures with selective autotumor reactivity.
Cancer immunology, immunotherapy : CII 1982;14(2):73-7.
-
1981: Merino F; Ahrlund-Richter L; Klein E
H-2 restriction of the cellular response in a methylcholanthrene sarcoma system studied with an F1 tumor and its H-2 loss variants.
Transplantation proceedings 1981;13(4):1874-6.
-
1981: Dalianis T; Ahrlund-Richter L; Merino F; Klein E; Klein G
Reduced humoral and cellular cytotoxic sensitivity in histocompatibility variants of the YAC (Moloney) lymphoma.
Immunogenetics 1981;12(3-4):371-80.
-
1980: Gunvén P; Klein G; Klein E; Norin T; Singh S
Surface immunoglobulins on Burkitt's lymphoma biopsy cells from 91 patients.
International journal of cancer. Journal international du cancer 1980;25(6):711-9.
Sign-in to see more
